Basic Information
| LncRNA/CircRNA Name | DUXAP9-206 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP, etc. |
| Sample | NSCLC tumour tissues, NSCLC cell lines (95D, A549, Calu-1, H1299, H1650, NCIH1703, NCI-H1975, NCI-H2009, NCI-H2030, NCI-H460, HCC827, PC9 and SK-MES-1) |
| Expression Pattern | up-regulated |
| Function Description | a cytoplasmic lncRNA, DUXAP9 206 is overexpressed in NSCLC cells and closely related to NSCLC clinical features and poor patient survival. We reveal that DUXAP9 206 induced NSCLC cell proliferation and metastasis by directly interacting with Cbl b, an E3 ubiquitin ligase, and reducing the degradation of epidermal growth factor receptor (EGFR) and thereby augmenting EGFR signaling in NSCLC. Notably, correlations between DUXAP9 206 and activated EGFR signaling were also validated in NSCLC patient specimens. |
| Pubmed ID | 30515972 |
| Year | 2018 |
| Title | LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression |
External Links
| Links for DUXAP9-206 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |